July 31, 2025: Pragmatic Trialists Share Strategies for Monitoring Changes in Usual Care

Pragmatic clinical trials are conducted as part of routine healthcare delivery and often compare an intervention to usual care. To do this, researchers must understand, monitor, and document standard care at participating research sites.

At the NIH Pragmatic Trials Collaboratory’s 2025 Annual Steering Committee Meeting, Duke University’s Emily O’Brian asked a panel of trialists about the strategies they used to define and document usual care. The panelists included Rachel Winer, co–principal investigator (PI) of STEP-2;, Richard Platt, co-PI of INSPIRE; and Christine Goertz, co-PI of IMPACt-LBP.

Key Strategies

  • Establish a community of individuals who are interested in and committed to answering the research question
  • Develop relationships: visit each site and have monthly coaching calls
  • Get commitment in advance from sites to hold their practice constant for the duration of the trial
  • Have sites complete readiness surveys or feasibility assessments that include questions about potential upcoming quality improvement initiatives
  • Minimize burden on sites as much as possible

The Navigating the Unknown chapter of the Living Textbook includes  descriptions of unanticipated challenges that may occur during the years-long course of a study that can have profound effects on usual care, including:

These challenges all require close collaboration with research partners to develop solutions.

This summer, we are sharing highlights from the 2025 Annual Steering Committee Meeting. Access the complete collection of meeting materials.

January 13, 2024: STEP-2 Trial of Cervical Cancer Screening Interventions Joins the NIH Collaboratory

Headshots of Drs. Rachel Winer, Amanda Petrik, and Jasmin Tiro
From left to right: Dr. Rachel Winer, Dr. Amanda Petrik, and Dr. Jasmin Tiro, principal investigators of the STEP-2 trial

The NIH Pragmatic Trials Collaboratory is pleased to welcome the STEP-2 trial (Self-Testing for Cervical Cancer in Priority Populations) to its portfolio of innovative NIH Collaboratory Trials.

Only half of eligible patients in US federally qualified health centers were screened for cervical cancer in 2021. The COVID-19 pandemic exacerbated these disparities. Distribution of human papillomavirus (HPV) self-sampling kits to patients is a widely adopted strategy in other countries but is nascent in the United States.

The STEP-2 study team will conduct a cluster randomized trial in federally qualified health centers in Oregon and Washington to evaluate the comparative effectiveness and cost-effectiveness of in-clinic distribution of self-sampling kits, in-clinic plus mailed distribution, and usual care. The project is supported by a grant award from the National Cancer Institute.

Rachel Winer, Amanda Petrik, and Jasmin Tiro are the principal investigators for the STEP-2 trial. Winer is a professor of epidemiology at the University of Washington. Petrik is an investigator at the Kaiser Permanente Center for Health Research. Tiro is a professor of public health sciences at the University of Chicago.

Learn more about the STEP-2 trial.